PBYI - Puma Biotechnology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.40
+0.46 (+2.10%)
As of 12:34PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close21.94
Open21.97
Bid22.33 x 100
Ask22.37 x 900
Day's Range21.94 - 22.54
52 Week Range17.60 - 108.50
Volume361,372
Avg. Volume1,239,789
Market Cap854.224M
Beta (3Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-5.59
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.78
Trade prices are not sourced from all markets
  • Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
    Market Realist6 days ago

    Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results

    On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%. On November 8, Portola Pharmaceuticals stock price closed at $23.14, which was ~21.41% growth from its previous close of $19.06. On November 7, Portola Pharmaceuticals stock price closed at $19.06, which was ~2.80% growth from its previous close of $18.54. On November 7, the company hit its 52-week low of $18.18.

  • GlobeNewswire6 days ago

    Investor Expectations to Drive Momentum within Matson, Craft Brew Alliance, Easterly Government Properties, Novanta, Ascena Retail Group, and Puma Biotechnology — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire8 days ago

    Puma Biotechnology to Present at Credit Suisse Healthcare Conference

    Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:10 a.m.

  • ACCESSWIRE8 days ago

    Biotech Stocks and the Midterm Elections

    HENDERSON, NV / ACCESSWIRE / November 7, 2018 / Midterm elections are expected to result in a split Congress, which should increase predictability for the biotech industry, and prevent, what some see as disruptive, government dictated pricing, less likely than if there is a Congress controlled by one party. Propanc Biopharma, Inc. (PPCB) is one biotech firm you should look at today. The FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer.

  • NERLYNX: Market Expansion and Label Expansion
    Market Realist8 days ago

    NERLYNX: Market Expansion and Label Expansion

    In a press release on July 31, Puma Biotechnology (PBYI) announced that Health Canada would review the company’s New Drug Submission for NERLYNX in the extended adjuvant setting for early-stage HER2-positive breast cancer after Herceptin-based adjuvant therapy.

  • NERLYNX: Major Growth Driver for PBYI
    Market Realist9 days ago

    NERLYNX: Major Growth Driver for PBYI

    Puma Biotechnology (PBYI) reported net sales of $52.6 million for NERLYNX in the third quarter, which is higher than its revenues of $50.8 million reported in the second quarter. According to the company’s third-quarter earnings conference call, Puma Biotechnology has attributed the growth to an increase in the number of patients being prescribed NERLYNX and patients choosing to stay on the therapy.

  • Puma Biotechnology: Revenue Projections for 2018
    Market Realist9 days ago

    Puma Biotechnology: Revenue Projections for 2018

    According to Puma Biotechnology’s (PBYI) third-quarter earnings conference call, the company expects NERLYNX’s net product revenues to be $175 million–$200 million for 2018. The company has provided a conservative guidance range—assuming that there might be lower patient starts in November and December due to the holidays.

  • Puma Biotechnology: Analysts’ Recommendations
    Market Realist9 days ago

    Puma Biotechnology: Analysts’ Recommendations

    On November 1, Puma Biotechnology (PBYI) closed at $20.07, which was 48.01% lower than its previous closing price. The stock has fallen  78.34% from $92.65 on January 2 to $20.07 on November 2. Puma Biotechnology stock rose 13.90% compared to its previous closing price and closed at $22.86 on November 5.

  • Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down
    Zacks10 days ago

    Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down

    Puma Biotech (PBYI) betters loss estimates in Q3. However, its only marketed drug, Nerlynx, disappoints with low sequential growth and as a result, shares take a hit.

  • Here's Why Puma Biotechnology Inc. Is Getting Hammered Today
    Motley Fool13 days ago

    Here's Why Puma Biotechnology Inc. Is Getting Hammered Today

    Sales of the company's lead drug just aren't living up to expectations.

  • Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates
    Zacks14 days ago

    Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates

    Puma Biotech (PBYI) delivered earnings and revenue surprises of 65.42% and 13.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Why Puma Biotechnology, Inc. Stock Is Getting Crushed Today
    Motley Fool14 days ago

    Why Puma Biotechnology, Inc. Stock Is Getting Crushed Today

    Puma's third-quarter numbers fail to impress Wall Street.

  • Business Wire14 days ago

    Puma Biotechnology Reports Third Quarter 2018 Financial Results

    Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2018. Unless otherwise stated, all comparisons are for the third quarter 2018 compared to the third quarter 2017.

  • Puma Biotech (PBYI) Q3 Earnings Preview: What to Look Out For
    Zacks21 days ago

    Puma Biotech (PBYI) Q3 Earnings Preview: What to Look Out For

    Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire28 days ago

    Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

    Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, November 1, 2018 following release of its third quarter 2018 financial results. Please dial in at least ten minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.

  • Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance
    Zacks28 days ago

    Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance

    Puma Biotech (PBYI) focuses on improving sales of its flagship and the only approved product Nerlynx. The drug's label expansion programs also appear promising.

  • GlobeNewswire29 days ago

    Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wirelast month

    Celcuity Announces Clinical Trial Collaboration with Puma Biotechnology and West Cancer Center

    Celcuity Inc. (CELC), a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, today announced a clinical trial agreement with Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, and West Cancer Center, to conduct a Phase II clinical trial. This open-label Phase II trial will evaluate the efficacy and safety of Puma’s drug, NERLYNX ®(neratinib), and chemotherapy in up to 27 early stage triple-negative breast cancer patients selected with Celcuity’s CELx HER2 Signaling Function (“CELx HSF”) Test. Under this agreement, West Cancer Center will serve as the sponsor and principal investigator of the trial and is responsible for enrolling patients and managing clinical data.

  • Business Wirelast month

    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on October 9, 2018, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 18,750 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017, and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

  • 3 Top Mid-Cap Stocks to Buy in October
    Motley Foollast month

    3 Top Mid-Cap Stocks to Buy in October

    These high-growth mid-cap stocks are just what the doctor ordered.

  • Business Wirelast month

    Puma Biotechnology’s Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX® (neratinib) in China

    Puma Biotechnology, Inc. has been advised that its licensing partner CANbridge Pharmaceutical Inc received confirmation that China’s National Medical Products Administration has accepted its New Drug Application for NERLYNX® for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab based-therapy.

  • Business Wire2 months ago

    Puma Biotechnology to Present at Cantor Global Healthcare Conference

    Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 1:10 p.m.

  • Business Wire2 months ago

    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on September 5, 2018 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 31,125 shares of Puma common stock to four new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Puma Biotech Gets EU Nod for Breast Cancer Drug Nerlynx
    Zacks2 months ago

    Puma Biotech Gets EU Nod for Breast Cancer Drug Nerlynx

    Puma Biotech (PBYI) gains EU approval for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

  • The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
    Zacks2 months ago

    The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

    The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals